

II)afe	Pulse (Beats/min)	_	Resp (Rate/min)	Temp (F)	Height (cms)	Weight	Percentage	Fat Level	Body Age (Years)	BMI	Circum	Hip (cms)	(cms)	Waist & Hip Ratio	User
24-02-2024 15:12			20 Rate/min	97 F	159 cms	83 Kgs	%	%	Years	32.83	111 cms	117 cms	cms		AHLL09262

II)afe	Pulse (Beats/min)	_	Resp (Rate/min)	Temp (F)	Height (cms)	Weight	Percentage	Fat Level	Body Age (Years)	BMI	Circum	Hip (cms)	(cms)	Waist & Hip Ratio	User
24-02-2024 15:12			20 Rate/min	97 F	159 cms	83 Kgs	%	%	Years	32.83	111 cms	117 cms	cms		AHLL09262

II)afe	Pulse (Beats/min)	_	Resp (Rate/min)	Temp (F)	Height (cms)	Weight	Percentage	Fat Level	Body Age (Years)	BMI	Circum	Hip (cms)	(cms)	Waist & Hip Ratio	User
24-02-2024 15:12			20 Rate/min	97 F	159 cms	83 Kgs	%	%	Years	32.83	111 cms	117 cms	cms		AHLL09262

Name: Mrs. NAGA VENKATA SAILAKSHMI

Age/Gender: 55 Y/F Address: pune

Location: PUNE, MAHARASHTRA

Doctor:

Department: GENERAL

Rate Plan: AUNDH_06042023

Sponsor: ARCOFEMI HEALTHCARE LIMITED

Consulting Doctor: Dr. PRADNYA NIKAM

Doctor's Signature

MR No: CAUN.0000140650 Visit ID: CAUNOPV167057 Visit Date: 24-02-2024 09:24

Discharge Date:

Referred By: SELF

Name: Mrs. NAGA VENKATA SAILAKSHMI

Age/Gender: 55 Y/F Address: pune

Location: PUNE, MAHARASHTRA

Doctor:

Department: GENERAL

Rate Plan: AUNDH_06042023

Sponsor: ARCOFEMI HEALTHCARE LIMITED

Consulting Doctor: Dr. ARPITA KRISHNA

Doctor's Signature

MR No: CAUN.0000140650 Visit ID: CAUNOPV167057 Visit Date: 24-02-2024 09:24

Discharge Date:

Referred By: SELF

Name: Mrs. NAGA VENKATA SAILAKSHMI

Age/Gender: 55 Y/F Address: pune

Location: PUNE, MAHARASHTRA

Doctor:

Department: GENERAL
Rate Plan: AUNDH_06042023

Sponsor: ARCOFEMI HEALTHCARE LIMITED

Consulting Doctor: Dr. RUCHIKA SRIVASTAVA

HT-CHIEF COMPLAINTS AND PRESENT KNOWN ILLNESS

SYSTEMIC REVIEW

HT-HISTORY

PHYSICAL EXAMINATION

SYSTEMIC EXAMINATION

IMPRESSION

RECOMMENDATION

Doctor's Signature

MR No: CAUN.0000140650 Visit ID: CAUNOPV167057 Visit Date: 24-02-2024 09:24

Discharge Date:

Referred By: SELF

II)afe	Pulse (Beats/min)	_	Resp (Rate/min)	Temp (F)	Height (cms)	Weight	Percentage	Fat Level	Body Age (Years)	BMI	Circum	Hip (cms)	(cms)	Waist & Hip Ratio	User
24-02-2024 15:12			20 Rate/min	97 F	159 cms	83 Kgs	%	%	Years	32.83	111 cms	117 cms	cms		AHLL09262

II)afe	Pulse (Beats/min)	_	Resp (Rate/min)	Temp (F)	Height (cms)	Weight	Percentage	Fat Level	Body Age (Years)	BMI	Circum	Hip (cms)	(cms)	Waist & Hip Ratio	User
24-02-2024 15:12			20 Rate/min	97 F	159 cms	83 Kgs	%	%	Years	32.83	111 cms	117 cms	cms		AHLL09262

Mrs. NAGA VENKATA SAILAKSHMI

Age/Gender: 55 Y/F 55 Y/ pune Address:

PUNE, MAHARASHTRA Location:

Doctor:

Department: GENERAL Rate Plan: AUNDH_06042023

ARCOFEMI HEALTHCARE LIMITED Sponsor:

Consulting Doctor: Dr. VIDYA DESHPANDE

HT-CHIEF COMPLAINTS AND PRESENT KNOWN ILLNESS

SYSTEMIC REVIEW

HT-HISTORY

PHYSICAL EXAMINATION

SYSTEMIC EXAMINATION

IMPRESSION

RECOMMENDATION

Doctor's Signature

MR No: CAUN.0000140650 Visit ID: CAUNOPV167057 Visit Date: 24-02-2024 09:24

Discharge Date:

Referred By: SELF Mrs. NAGA VENKATA SAILAKSHMI

Age/Gender: 55 Y/F pune Address:

PUNE, MAHARASHTRA Location:

Doctor:

Department: GENERAL Rate Plan: AUNDH_06

AUNDH_06042023

ARCOFEMI HEALTHCARE LIMITED Sponsor: Consulting Doctor: Dr. NANDINI SUDHIR BHAGAT

HT-CHIEF COMPLAINTS AND PRESENT KNOWN ILLNESS

SYSTEMIC REVIEW

HT-HISTORY

PHYSICAL EXAMINATION

SYSTEMIC EXAMINATION

IMPRESSION

RECOMMENDATION

Doctor's Signature

MR No: CAUN.0000140650 Visit ID: CAUNOPV167057 Visit Date: 24-02-2024 09:24

Discharge Date:

Referred By: SELF



Patient Name	: Mrs. NAGA VENKATA SAILAKSHMI	Age/Gender	: 55 Y/F
UHID/MR No.	: CAUN.0000140650	OP Visit No	: CAUNOPV167057
Sample Collected on	:	Reported on	: 24-02-2024 16:46
LRN#	: RAD2246967	Specimen	:
Ref Doctor	: SELF		
Emp/Auth/TPA ID	: 367478		

DEPARTMENT OF RADIOLOGY

ULTRASOUND - WHOLE ABDOMEN

<u>Liver</u> appears normal in size, shape and **shows enhanced in echotexture.**

No focal lesion is seen. PV and CBD are normal. No dilatation of the intrahepatic biliary radicals.

<u>Gall bladder</u> is well distended. No evidence of calculus. Wall thickness appears normal. No evidence of periGB collection. No evidence of focal lesion is seen.

Spleen appears normal. No focal lesion seen. Spleenic vein appears normal.

<u>Pancreas</u> appears normal in echopattern. No focal/mass lesion/calcification. No evidence of peripancreatic free fluid or collection. Pancreatic duct appears normal.

Both <u>the kidneys</u> appear normal in size, shape and echopattern. Cortical thickness and C M differentiation are maintained. No calculus / hydronephrosis seen on either side.

Right kidney - 9.7 x 4.6 cm.

Left kidney $-9.5 \times 5.4 \text{ cm}$.

<u>Urinary Bladder</u>: - is well distended and appears normal. No evidence of any wall thickening or abnormality. No evidence of any intrinsic or extrinsic bladder abnormality detected.

Uterus Hysterectomy status.

No obvious free fluid or lymphadenopathy is noted in the abdomen.

IMPRESSION:-

• Grade I fatty liver.



: Mrs. NAGA VENKATA SAILAKSHMI

Age/Gender

: 55 Y/F

• No other significant abnormality detected.

Suggest – clinical correlation.

(The sonography findings should always be considered in correlation with the clinical and other investigation finding where applicable.) It is only a professional opinion, not valid for medico legal purpose.

Dr. SUHAS SANJEEV KATHURIA MBBS,DMRE, RADIOLOGY

Radiology







Certificate No: MC-5697

Patient Name

: Mrs.NAGA VENKATA SAILAKSHMI

Age/Gender

: 55 Y 6 M 23 D/F : CAUN.0000140650

UHID/MR No Visit ID

: CAUNOPV167057

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID

: 367478

Collected

: 24/Feb/2024 09:33AM

Received

: 24/Feb/2024 01:35PM

Reported

: 24/Feb/2024 03:39PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEDADTMENT OF LIVEWATOR OGA

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

RBC's are Normocytic Normochromic, WBC's are normal in number and morphology Platelets are Adequate No Abnormal cells/hemoparasite seen.

Page 1 of 14

DR.Sanjay Ingle M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:BED240048264









: Mrs.NAGA VENKATA SAILAKSHMI

Age/Gender

: 55 Y 6 M 23 D/F

UHID/MR No

: CAUN.0000140650

Visit ID Ref Doctor : CAUNOPV167057

Emp/Auth/TPA ID

: Dr.SELF : 367478 Collected

: 24/Feb/2024 09:33AM

Received

: 24/Feb/2024 01:35PM

Reported

: 24/Feb/2024 03:39PM

Status

: Final Report

Dia Dat Danas

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
IEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	12.6	g/dL	12-15	Spectrophotometer
PCV	37.10	%	36-46	Electronic pulse & Calculation
RBC COUNT	4.61	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	80.5	fL	83-101	Calculated
MCH	27.4	pg	27-32	Calculated
MCHC	34.1	g/dL	31.5-34.5	Calculated
R.D.W	15	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	9,210	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (I	DLC)			
NEUTROPHILS	71.8	%	40-80	Electrical Impedance
LYMPHOCYTES	18.2	%	20-40	Electrical Impedance
EOSINOPHILS	3.2	%	1-6	Electrical Impedance
MONOCYTES	6.2	%	2-10	Electrical Impedance
BASOPHILS	0.6	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	6612.78	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1676.22	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	294.72	Cells/cu.mm	20-500	Calculated
MONOCYTES	571.02	Cells/cu.mm	200-1000	Calculated
BASOPHILS	55.26	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	3.95		0.78- 3.53	Calculated
PLATELET COUNT	343000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	14	mm at the end of 1 hour	0-20	Modified Westergren
ERIPHERAL SMEAR				

RBC's are Normocytic Normochromic,

WBC's are normal in number and morphology

Page 2 of 14

DR.Sanjay Ingle M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:BED240048264









: Mrs.NAGA VENKATA SAILAKSHMI

Age/Gender

: 55 Y 6 M 23 D/F

UHID/MR No Visit ID

: CAUN.0000140650 : CAUNOPV167057

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID

: 367478

Collected

: 24/Feb/2024 09:33AM

Received

: 24/Feb/2024 01:35PM

Reported

: 24/Feb/2024 03:39PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Platelets are Adequate

No Abnormal cells/hemoparasite seen.

Page 3 of 14



DR.Sanjay Ingle M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:BED240048264







: Mrs.NAGA VENKATA SAILAKSHMI

Age/Gender

: 55 Y 6 M 23 D/F

UHID/MR No

: CAUN.0000140650

Visit ID

: CAUNOPV167057

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 367478

Collected

: 24/Feb/2024 09:33AM

Received

: 24/Feb/2024 01:35PM

Reported

: 24/Feb/2024 05:32PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
BLOOD GROUP ABO AND RH FACT	FOR , WHOLE BLOOD EDTA		*	
BLOOD GROUP TYPE	0			Microplate Hemagglutination
Rh TYPE	Positive			Microplate Hemagglutination

Page 4 of 14



Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:BED240048264









: Mrs.NAGA VENKATA SAILAKSHMI

Age/Gender

: 55 Y 6 M 23 D/F

UHID/MR No

: CAUN.0000140650

Visit ID Ref Doctor : CAUNOPV167057

Emp/Auth/TPA ID

: Dr.SELF : 367478

Collected

: 24/Feb/2024 09:33AM

Received

: 24/Feb/2024 01:41PM

Reported

: 24/Feb/2024 02:10PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING, NAF PLASMA	113	mg/dL	70-100	HEXOKINASE

Comment:

As per American Diabetes Guidelines, 2023

F,		
Fasting Glucose Values in mg/dL	Interpretation	
70-100 mg/dL	Normal	
100-125 mg/dL	Prediabetes	
≥126 mg/dL	Diabetes	
<70 mg/dL	Hypoglycemia	

Note:

1.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.

2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 5 of 14



DR.Sanjay Ingle M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:PLF02112191

This test has been performed at Apollo Health and Lifestyle ltd- Sadashiv Peth Pune, Diagnostics Lab

Centriole, Plot #90, Survey #129, 130/1+2, ITI Road,







: Mrs.NAGA VENKATA SAILAKSHMI

Age/Gender

: 55 Y 6 M 23 D/F

UHID/MR No

: CAUN.0000140650

Visit ID Ref Doctor : CAUNOPV167057

Emp/Auth/TPA ID

: Dr.SELF

: 367478

Collected

: 24/Feb/2024 09:33AM

Received

: 24/Feb/2024 01:34PM : 24/Feb/2024 08:31PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C (GLYCATED HEMOGLOBIN), W	HOLE BLOOD EDTA		*	
HBA1C, GLYCATED HEMOGLOBIN	7.1	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	157	mg/dL	1	Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %	
NON DIABETIC	<5.7	
PREDIABETES	5.7 – 6.4	
DIABETES	≥ 6.5	
DIABETICS		
EXCELLENT CONTROL	6 – 7	
FAIR TO GOOD CONTROL	7 – 8	
UNSATISFACTORY CONTROL	8 – 10	
POOR CONTROL	>10	

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control A: HbF >25%
 - B: Homozygous Hemoglobinopathy.

(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 6 of 14



SIN No:EDT240021661

DR. MANISH T. AKARE M.B.B.S, MD(Path.) Consultant Pathologist









: Mrs.NAGA VENKATA SAILAKSHMI

Age/Gender

: 55 Y 6 M 23 D/F

UHID/MR No

: CAUN.0000140650

Visit ID Ref Doctor : CAUNOPV167057

Emp/Auth/TPA ID

: 367478

: Dr.SELF

Collected Received

: 24/Feb/2024 09:33AM : 24/Feb/2024 01:51PM

Reported

: 24/Feb/2024 07:52PM

Status

Sponsor Name

: Final Report : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIPID PROFILE , SERUM			*	
TOTAL CHOLESTEROL	238	mg/dL	<200	CHO-POD
TRIGLYCERIDES	194	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	45	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	193	mg/dL	<130	Calculated
LDL CHOLESTEROL	154.17	mg/dL	<100	Calculated
VLDL CHOLESTEROL	38.88	mg/dL	<30	Calculated
CHOL / HDL RATIO	5.29		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- 4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 400 mg/dL. When Triglycerides are more than 400 mg/dL LDL cholesterol is a direct measurement.

Page 7 of 14

DR. MANISH T. AKARE M.B.B.S, MD(Path.) Consultant Pathologist

SIN No:SE04640139







: Mrs.NAGA VENKATA SAILAKSHMI

Age/Gender

: 55 Y 6 M 23 D/F

UHID/MR No

: CAUN.0000140650

Visit ID Ref Doctor : CAUNOPV167057

Emp/Auth/TPA ID

: Dr.SELF : 367478

Collected

: 24/Feb/2024 09:33AM : 24/Feb/2024 01:51PM

Received

: 24/Feb/2024 07:52PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.54	mg/dL	0.3–1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.09	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.45	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	18.55	U/L	<35	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	20.9	U/L	<35	IFCC
ALKALINE PHOSPHATASE	121.24	U/L	30-120	IFCC
PROTEIN, TOTAL	8.12	g/dL	6.6-8.3	Biuret
ALBUMIN	5.00	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	3.12	g/dL	2.0-3.5	Calculated
A/G RATIO	1.6		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:


1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI .• Disproportionate increase in AST, ALT compared with ALP. • Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.• ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment: Albumin-Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time) helps.

Page 8 of 14



SIN No:SE04640139











: Mrs.NAGA VENKATA SAILAKSHMI

Age/Gender

: 55 Y 6 M 23 D/F

UHID/MR No

: CAUN.0000140650

Visit ID Ref Doctor : CAUNOPV167057

Emp/Auth/TPA ID

: Dr.SELF : 367478 Collected

: 24/Feb/2024 09:33AM

Received

: 24/Feb/2024 01:51PM

Reported

: 24/Feb/2024 07:52PM

Status Sponsor Name : Final Report

.

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM							
CREATININE	0.72	mg/dL	0.55-1.02	Modified Jaffe, Kinetic			
UREA	20.69	mg/dL	17-43	GLDH, Kinetic Assay			
BLOOD UREA NITROGEN	9.7	mg/dL	8.0 - 23.0	Calculated			
URIC ACID	8.21	mg/dL	2.6-6.0	Uricase PAP			
CALCIUM	10.19	mg/dL	8.8-10.6	Arsenazo III			
PHOSPHORUS, INORGANIC	3.09	mg/dL	2.5-4.5	Phosphomolybdate Complex			
SODIUM	139.39	mmol/L	136–146	ISE (Indirect)			
POTASSIUM	4.8	mmol/L	3.5–5.1	ISE (Indirect)			
CHLORIDE	100.5	mmol/L	101–109	ISE (Indirect)			

Page 9 of 14

DR. MANISH T. AKARE M.B.B.S, MD(Path.) Consultant Pathologist

SIN No:SE04640139











: Mrs.NAGA VENKATA SAILAKSHMI

Age/Gender

: 55 Y 6 M 23 D/F

UHID/MR No

: CAUN.0000140650

Visit ID Ref Doctor : CAUNOPV167057

Emp/Auth/TPA ID

: Dr.SELF

: 367478

Collected

: 24/Feb/2024 09:33AM

Received

: 24/Feb/2024 01:51PM

Reported

: 24/Feb/2024 07:52PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	20.80	U/L	<38	IFCC

Page 10 of 14

M.B.B.S, MD(Path.) Consultant Pathologist

DR. MANISH T. AKARE

SIN No:SE04640139







: Mrs.NAGA VENKATA SAILAKSHMI

Age/Gender

: 55 Y 6 M 23 D/F

UHID/MR No

: CAUN.0000140650 : CAUNOPV167057

Visit ID Ref Doctor

Emp/Auth/TPA ID

: Dr.SELF : 367478

Collected

: 24/Feb/2024 09:33AM

Received

: 24/Feb/2024 01:51PM

Reported

: 24/Feb/2024 03:02PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
THYROID PROFILE TOTAL (T3, T4, TSH), SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	1.3	ng/mL	0.7-2.04	CLIA
THYROXINE (T4, TOTAL)	12.49	μg/dL	5.48-14.28	CLIA
THYROID STIMULATING HORMONE (TSH)	3.585	μIU/mL	0.34-5.60	CLIA

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)			
First trimester	0.1 - 2.5			
Second trimester	0.2 - 3.0			
Third trimester	0.3 – 3.0			

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions			
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis			
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.			
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism			
Low	High	High	High	ary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy			
Low	N	N	N	Subclinical Hyperthyroidism			
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism			
Low	N	High	High	Thyroiditis, Interfering Antibodies			
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes			
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma			

Page 11 of 14



SIN No:SPL24031795











: Mrs.NAGA VENKATA SAILAKSHMI

Age/Gender

: 55 Y 6 M 23 D/F : CAUN.0000140650

UHID/MR No Visit ID

: CAUNOPV167057

Ref Doctor

: Dr.SELF : 367478

Emp/Auth/TPA ID

Collected Received

: 24/Feb/2024 09:33AM : 24/Feb/2024 01:51PM

Reported

: 24/Feb/2024 03:02PM

Status Sponsor Name : Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:SPL24031795

This test has been performed at Apollo Health and Lifestyle ltd- Sadashiv Peth Pune, Diagnostics Lab



Page 12 of 14









: Mrs.NAGA VENKATA SAILAKSHMI

Age/Gender

: 55 Y 6 M 23 D/F

UHID/MR No

: CAUN.0000140650

Visit ID Ref Doctor : CAUNOPV167057

Emp/Auth/TPA ID

: Dr.SELF : 367478 Status

: 24/Feb/2024 02:16PM

: 24/Feb/2024 09:33AM

: 24/Feb/2024 01:42PM

: Final Report

Sponsor Name

Collected

Received

Reported

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
COMPLETE URINE EXAMINATION (CUE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
pH	<5.5		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	>1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	POSITIVE +		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET N	MOUNT AND MICROSCOPY	Y	*	
PUS CELLS	3 - 4	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2 - 3	/hpf	<10	MICROSCOPY
RBC	1 - 2	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

*** End Of Report ***

Result/s to Follow: LBC PAP TEST (PAPSURE)

Page 13 of 14

DR.Sanjay Ingle M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:UR2290376









: Mrs.NAGA VENKATA SAILAKSHMI

Age/Gender UHID/MR No

: 55 Y 6 M 23 D/F : CAUN.0000140650

Visit ID

: CAUNOPV167057

Ref Doctor

Emp/Auth/TPA ID : 367478

: Dr.SELF

Collected

: 24/Feb/2024 09:33AM : 24/Feb/2024 01:42PM

Received

: 24/Feb/2024 02:16PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Page 14 of 14



DR.Sanjay Ingle M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:UR2290376

